Skip to main content

Table 4 Sensory nerve conduction tests in patients with HD, ALS or CSA

From: Electrophysiological differences between Hirayama disease, amyotrophic lateral sclerosis and cervical spondylotic amyotrophy

  Median nerve Ulnar nerve U/M ratio
  Amplitude (μV) CV (m/s) Amplitude (μV) CV (m/s) Amplitude CV
HD Affected limb 50.1 ± 13.2& 62.1 ± 6.4& 42.5 ± 13.7& 60.1 ± 5.5 0.9 ± 0.4 1.0 ± 0.1
  Healthy limb 50.4 ± 12.1 61.2 ± 6.4 44.9 ± 11.4 60.5 ± 6.2 0.9 ± 0.3 1.0 ± 0.1
ALS Affected limb 31.7 ± 14.3*& 57.5 ± 8.3*& 31.9 ± 13.4*& 56.6 ± 6.9*& 0.9 ± 0.3 0.9 ± 0.1
  Healthy limb 37.6 ± 12.3* 57.8 ± 5.9* 34.8 ± 13.1* 56.2 ± 5.2* 0.9 ± 0.3 1.0 ± 0.1
CSA Affected limb 38.9 ± 13.2*& 57.6 ± 5.7*& 36.5 ± 11.3*& 57.1 ± 4.5*& 0.9 ± 0.2 0.9 ± 0.1
  Healthy limb 38.2 ± 11.8* 57.2 ± 4.3* 37.5 ± 11.7* 57.2 ± 4.3* 0.9 ± 0.3 0.9 ± 0.2
Normal controls   45.6 ± 15.2 60.7 ± 5.2 38.1 ± 11.1 60.5 ± 5.2 0.9 ± 0.2 0.9 ± 0.1
  1. *P < 0.0001, the affected (healthy) limbs of patients with ALS or CSA patients vs. the affected (healthy) limbs of patients with HD.
  2. &P < 0.0001, the affected limbs of patients with HD, ALS or CSA vs. the limbs of normal control.
  3. HD, Hirayama disease; ALS, amyotrophic lateral sclerosis; CSA, cervical spondylotic amyotrophy; CV, conduction velocities; U/M, ulnar/median.